Pirfenidone in idiopathic pulmonary fibrosis: Is there a role?

被引：0
作者：
Galal, I. [1 ]
机构：
[1] Ain Shams Univ Hosp, Dept Chest Dis, Cairo, Egypt
来源：
EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS | 2014年 / 63卷 / 04期
关键词：
D O I：
10.1016/j.ejcdt.2014.06.013
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：749 / 750
页数：2
相关论文
共 12 条
  • [1] Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
    Azuma, A
    Nukiwa, T
    Tsuboi, E
    Suga, M
    Abe, S
    Nakata, K
    Taguchi, Y
    Nagai, S
    Itoh, H
    Ohi, M
    Sato, A
    Kudoh, S
    Raghu, G
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (09) : 1040 - 1047
  • [2] Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis Test Properties and Minimal Clinically Important Difference
    du Bois, Roland M.
    Weycker, Derek
    Albera, Carlo
    Bradford, Williamson Z.
    Costabel, Ulrich
    Kartashov, Alex
    King, Talmadge E., Jr.
    Lancaster, Lisa
    Noble, Paul W.
    Sahn, Steven A.
    Thomeer, Michiel
    Valeyre, Dominique
    Wells, Athol U.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (12) : 1382 - 1389
  • [3] Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis
    du Bois, Roland M.
    Weycker, Derek
    Albera, Carlo
    Bradford, Williamson Z.
    Costabel, Ulrich
    Kartashov, Alex
    Lancaster, Lisa
    Noble, Paul W.
    Raghu, Ganesh
    Sahn, Steven A.
    Szwarcberg, Javier
    Thomeer, Michiel
    Valeyre, Dominique
    King, Talmadge E., Jr.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (04) : 459 - 466
  • [4] Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level
    Gurujeyalakshmi, G
    Hollinger, MA
    Giri, SN
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 1999, 276 (02) : L311 - L318
  • [5] Iyer SN, 1999, J PHARMACOL EXP THER, V289, P211
  • [6] Iyer SN, 1999, J PHARMACOL EXP THER, V291, P367
  • [7] NICE guidance on pirfenidone for treating idiopathic pulmonary fibrosis
    Landells, Linda J.
    Naidoo, Bhash
    Robertson, Janet
    Clark, Peter
    [J]. LANCET RESPIRATORY MEDICINE, 2013, 1 (03) : 191 - 192
  • [8] Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
    Noble, Paul W.
    Albera, Carlo
    Bradford, Williamson Z.
    Costabel, Ulrich
    Glassberg, Marilyn K.
    Kardatzke, David
    King, Talmadge E., Jr.
    Lancaster, Lisa
    Sahn, Steven A.
    Szwarcberg, Javier
    Valeyre, Dominique
    du Bois, Roland M.
    [J]. LANCET, 2011, 377 (9779) : 1760 - 1769
  • [9] Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
    Oku, Hisashi
    Shimizu, Toshikatsu
    Kawabata, Tomoji
    Nagira, Morio
    Hikita, Ichiro
    Ueyama, Azumi
    Matsushima, Shuuichi
    Torii, Mikinori
    Arimura, Akinori
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 590 (1-3) : 400 - 408
  • [10] Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
    Richeldi, Luca
    Ryerson, Christopher J.
    Lee, Joyce S.
    Wolters, Paul J.
    Koth, Laura L.
    Ley, Brett
    Elicker, Brett M.
    Jones, Kirk D.
    King, Talmadge E., Jr.
    Ryu, Jay H.
    Collard, Harold R.
    [J]. THORAX, 2012, 67 (05) : 407 - 411
12